Total Valuation
BioNTech SE has a market cap or net worth of CHF18.97B. The enterprise value is CHF6.84K.
Market CapCHF18.97B
Enterprise ValueCHF6.84K
Share Statistics
BioNTech SE has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders0.51%
Owned by Institutions2.82%
Financial Efficiency
BioNTech SE’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -3.14%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-3.14%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee353.10K
Profits Per Employee-139.78K
Employee Count7,807
Asset Turnover0.13
Inventory Turnover5.57
Valuation Ratios
The current PE Ratio of BioNTech SE is ―. BioNTech SE’s PEG ratio is -0.29.
PE Ratio―
PS Ratio7.10
PB Ratio1.02
Price to Fair Value1.02
Price to FCF72.58
Price to Operating Cash Flow27.41
PEG Ratio-0.29
Income Statement
In the last 12 months, BioNTech SE had revenue of 2.76B and earned -1.09B in profits. Earnings per share was -4.51.
Revenue2.76B
Gross Profit2.14B
Operating Income-623.87M
Pretax Income-1.01B
Net Income-1.09B
EBITDA-628.00M
Earnings Per Share (EPS)-4.51
Cash Flow
In the last 12 months, operating cash flow was 736.83M and capital expenditures -218.49M, giving a free cash flow of 518.34M billion.
Operating Cash Flow736.83M
Free Cash Flow518.34M
Free Cash Flow per Share10.00T>
Dividends & Yields
BioNTech SE pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change6.85%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)26.00
Important Dates
BioNTech SE upcoming earnings date is Nov 3, 2026, Before Open (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateNov 3, 2026
Ex-Dividend Date―
Financial Position
BioNTech SE as a current ratio of 7.54, with Debt / Equity ratio of 1.78%
Current Ratio7.54
Quick Ratio7.49
Debt to Market Cap<0.01
Net Debt to EBITDA11.79
Interest Coverage Ratio-45.74
Taxes
In the past 12 months, BioNTech SE has paid 81.93M in taxes.
Income Tax81.93M
Effective Tax Rate-0.08
Enterprise Valuation
BioNTech SE EV to EBITDA ratio is -19.39, with an EV/FCF ratio of 45.14.
EV to Sales4.42
EV to EBITDA-19.39
EV to Free Cash Flow45.14
EV to Operating Cash Flow27.81
Balance Sheet
BioNTech SE has CHF9.74B in cash and marketable securities with CHF315.97M in debt, giving a net cash position of CHF9.42B billion.
Cash & Marketable SecuritiesCHF9.74B
Total DebtCHF315.97M
Net CashCHF9.42B
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF71.34
Margins
Gross margin is 68.95%, with operating margin of -22.63%, and net profit margin of -39.59%.
Gross Margin68.95%
Operating Margin-22.63%
Pretax Margin-36.61%
Net Profit Margin-39.59%
EBITDA Margin-22.78%
EBIT Margin-36.12%
Analyst Forecast
The average price target for BioNTech SE is CHF100.76, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF100.76
Price Target Upside32.56% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast―
EPS Growth Forecast―